Department of Pharmacology and Laboratory of Cerebrovascular Pharmacology, College of Pharmaceutical Science, Soochow University, Suzhou 215123, China.
Evid Based Complement Alternat Med. 2013;2013:795365. doi: 10.1155/2013/795365. Epub 2013 Oct 29.
Qiangli Tianma Duzhong capsule (TMDZ), a Chinese herbal drug, is clinically used to improve functional outcome in patients with ischemic stroke in China. This study was conducted to establish whether postischemic long-term treatment with TMDZ could reduce the loss of injured hemisphere and confer the improvements of neurological outcome in chronic survival of rats with 2 h middle cerebral artery occlusion (MCAO)/reperfusion brain injury and its primary mechanisms. We found that TMDZ (44.5, 89, or 178 mg/kg), administered per os 6 h after the onset of ischemia and for 28 consecutive days, significantly improved the behavior deficits, beginning on day 7, and further improved later. TMDZ treatment also markedly reduced the tissue loss of the injured hemisphere and improved histopathology. In the meantime, TMDZ treatment could improve hemorrheology and inhibit platelet aggregation. These results provide the first evidence that post-ischemic long-term treatment with TMDZ confers the improvements of neurological outcome and the loss of injured hemisphere in an animal ischemic stroke model, and its mechanisms might be associated with the improvements of hemorrheology and the inhibition of platelet aggregation.
强力天麻杜仲胶囊（TMDZ）是一种中药，临床上用于改善中国缺血性脑卒中患者的功能预后。本研究旨在探讨缺血后长期应用 TMDZ 是否能减轻损伤半球的丢失，并改善 2 h 大脑中动脉闭塞/再灌注脑损伤慢性存活大鼠的神经功能预后及其主要机制。我们发现，TMDZ（44.5、89 或 178 mg/kg）在缺血后 6 h 开始口服给药，并连续 28 天给药，可显著改善行为缺陷，从第 7 天开始，并进一步改善。TMDZ 治疗还显著减少损伤半球的组织丢失并改善组织病理学。同时，TMDZ 治疗可改善血液流变学并抑制血小板聚集。这些结果首次提供了证据，证明缺血后长期应用 TMDZ 可改善动物缺血性脑卒中模型的神经功能预后和损伤半球的丢失，其机制可能与改善血液流变学和抑制血小板聚集有关。
